Skip to Content

Join the 'High Cholesterol - Familial Heterozygous' group to help and get support from people like you.

High Cholesterol - Familial Heterozygous Blog

Related terms: Familial Hypercholesterolemia, Heterozygous, Heterozygous Familial Hypercholesterolemia, Heterozygous FH, Hypercholesterolemia, Familial Heterozygous

Do Cholesterol Drugs Affect Aggression?

Posted 1 day 8 hours ago by Drugs.com

WEDNESDAY, July 1, 2015 – Cholesterol-lowering statin drugs might influence a person's aggressive behaviors, increasing or decreasing their irritability and violent tendencies, a new clinical trial suggests. Men taking statins typically become less aggressive, while women on statins tend to become more aggressive, according to findings published July 1 in the journal PLOS ONE. "Clinicians should be aware of this, and it's not bad for patients to be aware of it," said lead author Dr. Beatrice Golomb, a principal investigator at the University of California, San Diego School of Medicine. "If an individual develops a behavioral change, in my view medication should always be considered as a possibility." However, the effect appears to be minimal and needs to be verified with follow-up studies, said one outside expert, Robert Geffner, founding president of the Institute on Violence, Abuse & ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, Red Yeast Rice, High Cholesterol - Familial Heterozygous, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol, Lescol XL, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL)

Half of U.S. Hispanics With High Cholesterol Unaware They Have It: Study

Posted 8 days ago by Drugs.com

WEDNESDAY, June 24, 2015 – Nearly half of Hispanic people in the United States with high cholesterol levels aren't aware they have the health problem and more than two-thirds who are aware aren't being treated, a new study indicates. Reviewing data from more than 16,000 Hispanics between the ages of 18 and 74, the researchers found that about 44 percent of men and 40 percent of women had high cholesterol, greater proportions overall than among the general U.S. population. Almost one-third of all American adults have high levels of low-density lipoprotein (LDL) or "bad" cholesterol, according to the U.S. Centers for Disease Control and Prevention, and less than a third have the condition under control. High cholesterol levels are a major risk factor for developing heart disease or stroke since a build-up of the fatty substance can narrow blood vessels and hinder blood flow to the heart ... Read more

Related support groups: High Cholesterol, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia Type III (Elevated beta-VLDL + IDL), Hyperlipoproteinemia Type IV (Elevated VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL)

Health Tip: What's Behind High Cholesterol?

Posted 8 days ago by Drugs.com

-- High cholesterol is a risk factor for serious health problems, from heart attack to stroke. The National Heart Lung and Blood Institute mentions these possible causes: Eating a diet high in cholesterol-rich foods, such as meat, cheese, egg yolks and other animal products. Foods high in saturated and trans fats also increase cholesterol. Being overweight or lack of physical activity can lead to extra pounds and boost cholesterol. Being age 55 or older increases your risk of high cholesterol. Having an inherited condition called familial cholesterolemia leads to high cholesterol. Read more

Related support groups: Obesity, High Cholesterol, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL), Hyperlipoproteinemia Type III (Elevated beta-VLDL + IDL), Hyperlipoproteinemia Type IV (Elevated VLDL)

Can U.S. Health-Care System Afford New, Improved Cholesterol Drugs?

Posted 14 days ago by Drugs.com

THURSDAY, June 18, 2015 – A new class of powerful cholesterol drugs is poised to hit the market, and doctors are both hopeful about their potential, and worried that insurers won't pay for them. The drugs, known as PCSK9 inhibitors, can drastically cut LDL cholesterol – the "bad" kind linked to increased risks of heart attack and stroke. And they are expected to open up a new option for people who cannot take statins, the drugs that have been the standard for cholesterol-lowering since the 1980s. Last week, an advisory panel to the U.S. Food and Drug Administration recommended the agency approve two PCSK9 inhibitors: alirocumab (Praluent) and evolocumab (Repatha). The FDA, which usually follows the recommendations of its advisory panels, is expected to OK both drugs. Some cardiologists have heralded PCSK9 inhibitors as a breakthrough – particularly for patients who can't take statins ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Zetia, Rosuvastatin, Hypertriglyceridemia, Red Yeast Rice, High Cholesterol - Familial Heterozygous, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Ezetimibe, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol

FDA Advisers Recommend Approval of 2nd New Cholesterol Drug

Posted 10 Jun 2015 by Drugs.com

WEDNESDAY, June 10, 2015 – U.S. health officials recommended Wednesday the approval of a second new drug that's part of a novel class of medications that sharply cut "bad" LDL cholesterol. In an 11-4 vote, a U.S. Food and Drug Administration advisory panel endorsed the drug evolocumab (Repatha) for use in patients who are at very high risk for high cholesterol. On Tuesday, the same panel of experts recommended approval of a similar drug known as alirocumab (Praluent). Both medications belong to a new class of drugs called PCSK9 inhibitors. But the advisory panel reiterated concerns that the real benefits of these drugs need to be determined in long-term studies. While the FDA isn't compelled to follow the recommendations of its advisory committees, it usually does so. How these drugs will be prescribed will depend largely on what prescribing information the FDA writes for these ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous

Cholesterol Drugs May Lower Stroke Risk for Healthy Older Adults

Posted 19 May 2015 by Drugs.com

TUESDAY, May 19, 2015 – Healthy older adults who take cholesterol-lowering drugs may be cutting their risk of stroke, a new French study suggests. The study found that when people took medications called statins or fibrates, their risk of stroke over almost a decade went down by about one-third. But, lead researcher Dr. Christophe Tzourio, a professor of epidemiology at the University of Bordeaux and Inserm in France, doesn't think older people should start taking these drugs solely for stroke prevention. "Our results should not be interpreted as an indication for prescribing statins or fibrates to elderly individuals. We wouldn't recommend changing medications based on the results of only one study," he said. "The next step is to see whether we can replicate our findings or not," he added. The report was published May 19 in the BMJ. Statins include drugs such as Lipitor and Zocor. ... Read more

Related support groups: Ischemic Stroke, High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Transient Ischemic Attack, Tricor, Rosuvastatin, Hypertriglyceridemia, Red Yeast Rice, High Cholesterol - Familial Heterozygous, Livalo, Ischemic Stroke - Prophylaxis, Pravachol, High Cholesterol - Familial Homozygous, Thromboembolic Stroke Prophylaxis

Staying Fit May Delay Onset of High Cholesterol, Study Finds

Posted 11 May 2015 by Drugs.com

MONDAY, May 11, 2015 – Men who keep fit may find they delay normal age-related increases in blood cholesterol levels by up to 15 years, a new study suggests. It is common for cholesterol levels to rise with age and then decrease later in life, the study authors explained in background notes. Previous studies have shown that high cholesterol levels can be a risk factor for heart disease. Regular physical activity can lower this risk, the researchers said. "Exercise and being fit helps keep arteries clear by lowering 'bad' [LDL] cholesterol and boosting 'good' [HDL] cholesterol," explained study author Dr. Xuemei Sui, an assistant professor at the Arnold School of Public Health at the University of South Carolina in Columbia, S.C. "It also reduces other risk factors for atherosclerosis [narrowed arteries] and blood clots, such as high blood pressure, diabetes, obesity and stress," Sui ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Zetia, Rosuvastatin, Hypertriglyceridemia, Red Yeast Rice, High Cholesterol - Familial Heterozygous, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Ezetimibe, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol

Americans' Blood Triglyceride Levels Dropping: CDC

Posted 7 May 2015 by Drugs.com

THURSDAY, May 7, 2015 – Americans' levels of triglycerides – a type of fat in the blood – have dropped significantly in the past decade, according to a new federal study. Factors that may lower triglyceride levels include quitting smoking, weight loss, use of cholesterol-lowering drugs (such as statins) and improving dietary nutrition, the researchers said. "The news is encouraging," said Dr. Michael Miller, a professor at the University of Maryland School of Medicine in Baltimore. But Miller, who was not involved with the study, added that it is "certainly nothing to brag about when one out of every three middle-aged men 40 to 59, and nearly one out of every three women aged 60 and over continue to live with unhealthy triglyceride levels." Like the bad type of cholesterol – LDL – high levels of triglycerides raise the risk of clogged arteries and heart disease. Another expert, Dr. ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, Red Yeast Rice, High Cholesterol - Familial Heterozygous, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol, Lescol XL, Mevacor

New Drug Class Slashes 'Bad' Cholesterol, Review Finds

Posted 27 Apr 2015 by Drugs.com

MONDAY, April 27, 2015 – A new class of cholesterol drug could sharply cut "bad" LDL cholesterol in people who don't fare well on commonly used cholesterol-lowering medications called statins, a new research review confirms. The drugs, known as PCSK9 inhibitors, are not on the market yet. But the U.S. Food and Drug Administration (FDA) is expected to decide later this year on the first two medications in the class: evolocumab (Repatha) and alirocumab (Praluent). The review of 24 clinical trials found that PCSK9 inhibitors lowered people's LDL cholesterol by about 47 percent, on average. More important, the drugs seemed to cut the risk of heart attack or death from heart disease, according to the researchers. Experts did urge some caution, however: Trials so far have been short-term, and it's not clear whether the new cholesterol drugs really do extend people's lives, according to Dr. ... Read more

Related support groups: High Cholesterol, Niacin, Niaspan, High Cholesterol - Familial Heterozygous, Prevention of Cardiovascular Disease, High Cholesterol - Familial Homozygous, Slo-Niacin, Cardiovascular Risk Reduction, Niaspan ER, Vascepa, Cardiovascular Conditions and Disorders, Nicotinic Acid, Choloxin, Mipomersen, Nicotinex, Niacor B3, B3-500-Gr, Nico-400, Lorelco, Juxtapid

New Guidelines Would Greatly Boost Number of Young People on Statins

Posted 6 Apr 2015 by Drugs.com

MONDAY, April 6, 2015 – If all doctors followed new cholesterol guidelines aimed at children, almost half a million Americans aged 17 to 21 would be prescribed a cholesterol-lowering statin drug, a new study predicts. In 2011, the U.S. National Heart, Lung, and Blood Institute (NHLBI) issued new guidelines on reducing heart disease in adolescents and young adults. Those guidelines recommended that all people aged 17 to 21 get their blood levels of cholesterol checked, and statin treatment be initiated if cholesterol was at a certain level. In contrast, the American College of Cardiology (ACC) and American Heart Association (AHA) are sticking by adult-focused guidelines that more tightly restrict the use of statins for those under 40 years age. In the new study, researchers led by Dr. Holly Gooding of Boston Children's Hospital looked at data from more than 6,300 participants, aged 17 ... Read more

Related support groups: High Cholesterol, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia Type III (Elevated beta-VLDL + IDL), Hyperlipoproteinemia Type IV (Elevated VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL)

FDA Approves Merck’s Liptruzet (ezetimibe and atorvastatin), a New Product That Can Help Lower LDL Cholesterol

Posted 6 May 2013 by Drugs.com

Friday, May 3, 2013 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Liptruzet (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. Liptruzet (pronounced LIP-true-zett) contains ezetimibe, an efficacious LDL cholesterol lowering therapy, and atorvastatin, currently one of the most widely prescribed statins in the U.S.[1] Once-daily Liptruzet treats two sources of cholesterol by inhibiting both the absorption of cholesterol in the digestive tract – through ezetimibe – and the production of cholesterol in the liver – through atorvastatin. No incremental benefit of Liptruzet on cardiovascular morbidity and mortality over and above that de ... Read more

Related support groups: High Cholesterol, Lipitor, Atorvastatin, Zetia, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Ezetimibe, Hyperlipidemia

Cholesterol Levels Dropping in U.S. Adults, Mostly From Statin Use

Posted 17 Oct 2012 by Drugs.com

TUESDAY, Oct. 16 – When it comes to coronary artery disease in the United States, there's good news and bad news. The good news? Average levels of the worst forms of cholesterol are dropping among U.S. adults. The bad news? Americans are achieving those better numbers not so much by changing their diet or ramping up their exercise, but largely by taking statins: cholesterol-lowering medications. A comprehensive look at how Americans are faring in the battle against coronary artery disease shows that over about 22 years, total cholesterol and LDL (low-density lipoprotein cholesterol, often called "bad" cholesterol) have declined. But the percentage of adults taking anti-cholesterol medications has climbed as well. In addition to looking at the average levels of cholesterol and factors associated with increased risk of heart disease, the researchers noted whether participants were taking ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Rosuvastatin, High Cholesterol - Familial Heterozygous, Red Yeast Rice, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Lescol, Lescol XL, Mevacor, Fluvastatin, Altoprev, Pitavastatin

Cholesterol Levels Vary Widely by Country: Study

Posted 9 Apr 2012 by Drugs.com

MONDAY, April 9 – People's average cholesterol levels seem to rise and fall along with their countries' economies and ease of access to quality health care, according to a new study. Researchers examined data from thousands of patients with a history of high cholesterol (more than 200 milligrams per deciliter) in 36 countries, including the United States. The analysis revealed that countries with higher overall income levels, lower out-of-pocket health care costs, and high-performing and efficient health systems tend to have lower rates of high cholesterol among people who'd had a history of high cholesterol. For patients with no history of high cholesterol, there was no association between a country's economy and health care system and the risk of high cholesterol. Among the specific findings: Rates of total high cholesterol varied widely, ranging from 73 percent in Bulgaria to 24 ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous

Cholesterol Drug Shows Promise in Early Research

Posted 15 Nov 2011 by Drugs.com

TUESDAY, Nov. 15 – Preliminary trials indicate that a new drug designed to simultaneously boost good cholesterol while lowering bad cholesterol shows considerable promise, both on its own and in combination with standard statin medications. The drug evacetrapib is part of a class of so-called "cholesteryl ester transfer protein (CETP) inhibitors." Evacetrapib is the second CETP medication to undergo testing as a means to lower "bad" low-density lipoprotein cholesterol while raising "good" high-density lipoprotein cholesterol. Testing of the first drug in this class – Pfizer's torcetrapib – ended badly. A 15,000-person trial of torcetrapib conducted several years ago revealed that the medication (administered in combination with the statin Lipitor) was associated with an elevated risk for cardiovascular complications and even death. In that case, the trial was halted mid-stream and ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous

For Cholesterol Control, Experts Urge More Than Meds

Posted 29 Dec 2010 by Drugs.com

TUESDAY, Dec. 28 – Advances in medical science have made it easier than ever to lower dangerous cholesterol levels. A class of cholesterol-lowering drugs known as statins have proven particularly effective, reducing the risk for heart-related death by as much as 40 percent in people who have already suffered a heart attack, said Dr. Vincent Bufalino, president and chief executive of Midwest Heart Specialists and a spokesman for the American Heart Association. "People have said we need them in the drinking water because they are just so effective in lowering cholesterol," Bufalino said. But he and other doctors warn that when it comes to controlling cholesterol and enjoying overall health, nothing beats lifestyle changes, such as a heart-friendly diet and regular exercise. "Once we became a fast-food generation, it's just too easy to order it at the first window, pick it up at the ... Read more

Related support groups: High Cholesterol, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia Type III (Elevated beta-VLDL + IDL), Hyperlipoproteinemia Type IV (Elevated VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL)

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

High Cholesterol

Related Drug Support Groups

Lipitor, simvastatin, Crestor, pravastatin, atorvastatin, Zocor, lovastatin, Zetia, Vytorin, view more... rosuvastatin, Pravachol, ezetimibe, Lescol, Advicor, Lescol XL, Mevacor, Choloxin, Altoprev, fluvastatin, Altocor, Juvisync, dextrothyroxine sodium, simvastatin / sitagliptin, ezetimibe / simvastatin, lovastatin / niacin